about
Ex-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapyGalectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myelomaEffects of a novel proteasome inhibitor BU-32 on multiple myeloma cells.Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.Diagnostic delay and complications for older adults with multiple myelomaAngiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma.Recent advances in anti-angiogenic therapy of cancerAnti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer?Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma.3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.Angiogenesis and multiple myeloma.Multiple myeloma cells modify VEGF/IL-6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR-223.Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells.Effects of thalidomide on growth and VEGF-A expression in SW480 colon cancer cells.Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.STK405759 as a combination therapy with bortezomib or dexamethasone, in and multiple myeloma models
P2860
Q28535634-7B06F0D7-98F5-4186-BC2A-5362ACF6BE63Q28742668-F254E2DC-2304-4433-A90E-3F5CD3C1F708Q33675494-ACB4EDC7-8543-4D34-83F4-7231DBA17565Q33692555-B68539F4-C338-4922-A802-8CF7A83165FFQ33698897-153156A9-1751-4107-B555-B99BDEC89133Q37413352-E0326865-7B7B-4099-BAE4-F0AAC5213EF7Q37852512-E0EA8799-C486-49D1-AB53-8E246CF1B913Q38209789-E5C13AC6-F774-4F0A-86BE-DA10A686E879Q38647628-7202571E-EA00-4CEA-B2A2-9B058F7CDB41Q38832888-21D5ED79-A465-4234-A8E2-53848E054CFFQ39696428-2F3B0945-E1C4-4398-B485-EE54BE4F0434Q39881866-3902356A-E379-49A1-9F25-CAB9419670B1Q42357210-88F42C6A-D2E6-4358-8E55-F79DAA1AFEEDQ49513925-4EE652E4-E9FB-43F5-9600-F7F802A196B2Q53155413-7B5DB8F1-668E-4C99-9DB0-E5FE871D5125Q57174026-89F51A24-EE78-4C30-B3D7-DE77F41A1E1D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel anti-myeloma agents and angiogenesis.
@en
Novel anti-myeloma agents and angiogenesis.
@nl
type
label
Novel anti-myeloma agents and angiogenesis.
@en
Novel anti-myeloma agents and angiogenesis.
@nl
prefLabel
Novel anti-myeloma agents and angiogenesis.
@en
Novel anti-myeloma agents and angiogenesis.
@nl
P2093
P2860
P1433
P1476
Novel anti-myeloma agents and angiogenesis
@en
P2093
Evangelos Terpos
Konstantinos Anargyrou
Orhan Sezer
P2860
P304
P356
10.1080/10428190701861686
P577
2008-04-01T00:00:00Z